Drug intelligence / Profile preview

FP-1096

Development stage: Discontinued
Lead developer: FemmePharma
Modality: Small Molecules

Overview

FP-1096 (also known as PARDEL) is a small molecule drug developed as a novel treatment for endometriosis, a chronic and often painful condition in which tissue similar to the lining inside the uterus grows outside it. The drug was designed to reduce pain associated with endometriosis and demonstrated efficacy in clinical trials by significantly reducing painful symptoms with minimal side effects. Despite promising results in phase 3 studies, development of FP-1096 has been discontinued. The precise mechanism of action has not been publicly disclosed[1][2][3][9][10].

Brand names: PARDEL

Beyond the preview

Go deeper on FP-1096.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FP-1096.

Explore the full profile